NATICK, Mass., January 14, 2025--(BUSINESS WIRE)--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today ...

Allurion Technologies shares rose after agreeing to a private placement with expected gross proceeds of $2.5 million that will extend its runway through early 2026. The stock was up 13% to $3.37 ...

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a ...

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a subscription agreement with funds ...

Our 2025 plan includes scaling our new commercial strategy, advancing the Allurion Balloon through the FDA approval process, setting the company up for a profitable 2026, expanding our digital ...

The Allurion intragastric balloon (IGB) is inserted through the mouth into the patient's stomach endoscopically before being expanded with 550 milliliters of water. “Over the past decade, demand for ...

At 48 weeks, Allurion Balloon subjects had a greater than 50% responder rate and substantially greater weight loss than Control subjects Low rate of serious adverse events supports favorable ...

Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced topline results from the AUDACITY Food & Drug Administration (FDA) pivotal trial evaluating the ...

Allurion Technologies, Inc. (NYSE:ALUR), a medical device company specializing in surgical and medical instruments with a market capitalization of $27.77 million, announced the appointment of R. Jason ...

Allurion Technologies, Inc. (NYSE:ALUR), a medical device company specializing in surgical and medical instruments with a market capitalization of $27.77 million, announced the appointment of R.

438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial. And this offer includes a 2-Week FREE TRIAL plus Brad Thomas' FREE book. Analyst’s Disclosure: I/we have a ...